EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Evaluation of sulbactam/durlobactam activity and synergy against highly drug-resistant Acinetobacter baumannii strains

Justin Halim, Jeannete Bouzo, Valerie J Carabetta iD

JAC-Antimicrobial Resistance · 30.10.2025 · 7 (6)

DOI: 10.1093/jacamr/dlaf220 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAC-Antimicrobial Resistance, online erschienen am 19.11.2025. Verfasst von Justin Halim und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, Cooper Medical School of Rowan University, Camden, NJ 08103, USA. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, National Institute of General Medical Sciences.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Acinetobacter baumannii is a bacterial pathogen frequently implicated in healthcare-associated infections, with limited effective treatment options due to widespread antibiotic resistance. Sulbactam/durlobactam is a novel β-lactam/β-lactamase inhibitor (βL/βLI) combination recently approved for the treatment of hospital-associated bacterial pneumonia and ventilator-associated bacterial pneumonia due to A. baumannii.

Methods

We evaluated the in vitro activity of sulbactam/durlobactam alone and in combination with 15 clinically relevant antibiotics against 22 A. baumannii clinical isolates, including 21 extensively or pandrug-resistant strains (M1–M22) and one metallo-β-lactamase (MBL)-producing strain (BAA-3302). Susceptibility testing, chequerboard synergy assays, and static time-kill assays were performed to assess antimicrobial interactions.

Results

All 21 XDR/PDR isolates were susceptible to sulbactam/durlobactam (MIC < 4/4 mg/L), while the MBL-harbouring strain BAA-3302 showed intermediate susceptibility (MIC = 8/4 mg/L). Chequerboard assays revealed consistent synergy between sulbactam/durlobactam and multiple β-lactams and βL/βLI agents, including cefepime, meropenem, cefiderocol, ceftazidime–avibactam, and piperacillin–tazobactam, with ≥95% of strains showing synergistic effects. Selected combinations demonstrated rapid and sustained bactericidal activity against select strains in time-kill assays. Combinations with tetracyclines also showed synergy in select strains, particularly against the MBL-carrying isolate.

Conclusions

Sulbactam/durlobactam demonstrates strong activity against highly drug-resistant A. baumannii isolates and shows enhanced potency when combined with specific β-lactam and βL/βLI agents. Further investigation of sulbactam/durlobactam-based combination therapy is warranted as a therapeutic strategy for the treatment of carbapenem-resistant A. baumannii infections.

Autor:innen und Institutionen

  • Department of Biomedical Sciences, Cooper Medical School of Rowan University, Camden, NJ 08103, USA.
  • Rowan-Virtua School of Osteopathic Medicine, Stratford, NJ 08084, USA.

ORCID-Profile: Valerie J Carabetta

Förderung

  • NIGMS NIH HHS
  • National Institute of General Medical Sciences

Zitieren

APA

Halim, J., Bouzo, J., & Carabetta, V. J. (2025). Evaluation of sulbactam/durlobactam activity and synergy against highly drug-resistant Acinetobacter baumannii strains. JAC-Antimicrobial Resistance, 7(6). https://doi.org/10.1093/jacamr/dlaf220

Vancouver

Halim J, Bouzo J, Carabetta VJ. Evaluation of sulbactam/durlobactam activity and synergy against highly drug-resistant Acinetobacter baumannii strains. JAC-Antimicrobial Resistance. 2025;7(6). doi:10.1093/jacamr/dlaf220

BibTeX
@article{Halim2025,
  author = {Halim, Justin and Bouzo, Jeannete and Carabetta, Valerie J},
  title = {Evaluation of sulbactam/durlobactam activity and synergy against highly drug-resistant Acinetobacter baumannii strains},
  journal = {JAC-Antimicrobial Resistance},
  year = {2025},
  volume = {7},
  number = {6},
  doi = {10.1093/jacamr/dlaf220}
}
Kostenlos starten →